Autres langues BioCryst Pharmaceuticals, Inc. Berne S.E.

Actions

BO1

US09058V1035

Recherche biotechnologique et médicale

Cours en clôture Berne S.E. 11/09/2026			Varia. 5j.	Varia. 1 janv.
6,676 ^CHF	+1,13%		-16,76%	-

10/09	BioCryst Pharmaceuticals confronté à la pression concurrentielle dans le traitement de l'angioedème héréditaire, selon RBC	MT
10/09	BioCryst Pharmaceuticals, Inc. : RBC Capital Markets passe à neutre sur le dossier	ZM

Autres langues

10/09	BioCryst Pharmaceuticals Faces Competitive Pressure in Hereditary Angioedema Treatment, RBC Says
08/09	Pharvaris' genetic disorder drug meets main goal in late-stage trial
01/09	BioCryst to Present at Upcoming Investor Conference
25/08	BioCryst Pharmaceuticals Announces Approval Of ORLADEYO For Pediatric HAE Patients In Japan
25/08	BioCryst Pharmaceuticals Gets Japan Approval for Orladeyo in Young Children
25/08	BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
05/08	BioCryst Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2026
05/08	BioCryst Pharmaceuticals Q2 Earnings, Revenue Increase; 2026 Revenue Outlook Raised
05/08	BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
05/08	Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q2 EPS $0.30, vs. FactSet Est of $0.15
05/08	Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q2 Revenue $218.2M, vs. FactSet Est of $183.3M
05/08	BioCryst: Q2 Earnings Snapshot
05/08	BioCryst Reports Second Quarter 2026 Financial Results
22/07	BioCryst to Report Second Quarter 2026 Financial Results on August 5
15/07	BioCryst Pharmaceuticals, Inc. Announces Appointment of David W. Jenkins as Chief Scientific Officer, Effective July 15, 2026
15/07	BioCryst Appoints David W. Jenkins as Chief Scientific Officer
02/07	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/06	BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs
29/06	BioCryst to Discontinue Internal Discovery Programs, Close Birmingham Facility by Year-End
29/06	BioCryst Pharmaceuticals, Inc. Discontinues Internal Discovery Programs And Closes Birmingham Research Facility
29/06	BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2000 Value Benchmark
29/06	BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
29/06	BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 3000E Value Benchmark
29/06	BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 3000 Value Benchmark
29/06	BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell Small Cap Comp Value Benchmark